FULCRUM THERAPEUTICS, INC. Increase (Decrease) in Accounts and Other Receivables
FULCRUM THERAPEUTICS, INC. (FULC) reported Increase (Decrease) in Accounts and Other Receivables of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2024-02-27
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2023-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2023-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for fiscal 2023 was $0.00.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for fiscal 2022 was -$2.50M, a 600.00% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for fiscal 2021 was $500.00K, a 75.00% decline from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. increase (decrease) in accounts and other receivables for fiscal 2020 was $2.00M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 3 month as first filed | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 6 month as first filed | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 9 month as first filed | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | -$4.99M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | -$4.99M derived: sum of 3 quarters · filed 2024-02-27 | -$4.64M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | -$4.99M derived: sum of 2 quarters · filed 2024-02-27 | -$4.64M derived: sum of 3 quarters · filed 2024-02-27 | -$5.00M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-12-31 | -$4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$4.64M derived: sum of 2 quarters · filed 2024-02-27 | -$5.00M derived: sum of 3 quarters · filed 2024-02-27 | -$2.50M 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$13.00K derived: sum of 2 quarters · filed 2023-11-07 | $2.49M 10-Q · filed 2023-11-07 | -$2.49M 10-Q · filed 2022-11-08 | $4.99M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | -$357.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.14M 10-Q · filed 2023-08-03 | -$2.14M 10-Q · filed 2022-08-11 | $4.64M derived: sum of 3 quarters · filed 2023-08-03 | $4.64M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-15 | -$2.50M 10-Q · filed 2022-05-09 | $5.00M derived: sum of 2 quarters · filed 2023-06-26 | $5.00M derived: sum of 3 quarters · filed 2023-06-26 | $5.00M derived: sum of 4 quarters · filed 2023-06-26 | ||
| 2021-12-31 | $2.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $2.50M derived: sum of 2 quarters · filed 2023-06-26 | $2.50M derived: sum of 3 quarters · filed 2023-06-26 | $500.00K 10-K/A · filed 2023-06-26 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | -$2.00M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$2.00M 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | -$2.00M 10-Q · filed 2022-05-09 | ||||||
| 2020-12-31 | $2.00M 10-K/A · filed 2023-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |